drugset / Trial / NCT04518774
Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial
Phase 0
Unknown
8 enrolled
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd. · collabChinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of hepatocellular carcinoma patients.
Timeline
- Start
- 2020-08-15
- Primary completion
- 2021-06-15
- Completion
- 2021-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 1e+07 cells/kg | Other |
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 3e+07 cells/kg | Other |
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 9e+07 cells/kg | Other |